Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development ...
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback